Opus Genetics to report Phase 1/2 Cohort 1 topline data for OPGx-BEST1 gene therapy Sept. 9 webcast
IRD•What the study is evaluating
The readout will cover early clinical performance of a gene therapy aimed at improving vision outcomes in inherited retinal disease tied to BEST1 mutations.
Upcoming webcast and data readout
Opus Genetics said it will hold a Sept. 9, 2026 investor webcast to present topline Phase 1/2 Cohort 1 data for OPGx-BEST1.
The results have not yet been presented. Broader analyses are scheduled to be released at ophthalmology conferences later in September and October 2026.
